IMCLONE SYSTEMS INCORPORATED

ACCESS ERBITUX

ASSISTANCE TO OTHERS IN RESPECT OF HEALTH INSURANCE COVERAGE FOR PHARMACEUTICALS, NAMELY, ADMINISTERING PHARMACY REIMBURSEMENT PROGRAMS AND SERVICES;CHARITABLE ASSISTANCE TO OTHERS IN RESPECT OF HEALTH INSURANCE COVERAGE FOR PHARMACEUTICALS, NAMELY, PATIENT ASSISTANCE PROGRAM TO PROVIDE DRUGS FREE OF CHARGE TO LOW-INCOME PATIENTS WITHOUT PRESCRIPTION DRUG COVERAGE;

AKODAR

pharmaceutical preparation, namely monoclonal antibody regulating angiogenesis;

AMPLIPROBE

HYBRIDIZATION ASSAY KIT, NAMELY, CONTAINERS CONTAINING SPECIFIC SEQUENCES OF DNA MOLECULES FOR USE IN FIELDS OF MEDICINE AND MEDICAL RESEARCH;AMPLITUDE PROBE;

CETUXIMAB ERBITUX

THE MARK COMPRISES THE WORDS CETUXIMAB ERBITUX AND AN ANTIBODY DESIGN (SHOWN IN STIPPLING);PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER;CETUXIMAB;-;

CEVANA

pharmaceutical preparation, namely monoclonal antibody regulating angiogenesis;

CEVANA

Pharmaceutical preparations, namely, monoclonal antibodies for use in regulating angiogenesis;

ERBITUX

The mark comprises the word ERBITUX and an antibody design.;PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER;Color is not claimed as a feature of the mark.;

ERBITUX CETUXIMAB

The mark comprises the words ERBITUX CETUXIMAB and an antibody design (shown in stippling).;PHARMACEUTICAL PREPARATION, NAMELY, MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER;Color is not claimed as a feature of the mark.;CETUXIMAB;The stippling is for shading purposes.;

ERBITUX EXPANDS THE POSSIBILITIES OF CANCER THERAPY

MEDICAL INFORMATION SERVICES RENDERED TO THE PUBLIC BY MEANS OF A GLOBAL COMPUTER INFORMATION NETWORK, PERTAINING TO CANCER, CANCER RESEARCH, TREATMENT OF CANCER, PHARMACEUTICAL PREPARATIONS FOR TREATMENT OF CANCER, VACCINES AND DIAGNOSTIC PREPARATIONS;

ERBLOC

pharmaceutical preparation, namely monoclonal antibody for the treatment of cancer;

ERBLOC

PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER;EMERGENCY ROOM BLOCK;

ERBLOC

PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CANCER; PHARMACEUTICAL PREPARATIONS REGULATING ANGIOGENESIS; PHARMACEUTICAL PREPARATIONS FOR IMMUNOLOGY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF PSORIASIS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF OBESITY; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF FIBROSIS; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF INFLAMMATION; PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF PRE-ECLAMPSIA; VACCINES;DIAGNOSTIC PREPARATIONS FOR RESEARCH USE AND FOR CLINICAL OR MEDICAL LABORATORY USE;PROVIDING COMPUTERIZED ONLINE MEDICAL AND SCIENTIFIC RESEARCH INFORMATION IN THE FIELDS OF IMMUNOLOGY, ONCOLOGY AND ANGIOGENESIS;

HEROES IN ONCOLOGY

ORGANIZING AND CONDUCTING AWARD PROGRAMS AND SPECIAL EVENTS TO RECOGNIZE ADVANCES IN THE FIELD OF ONCOLOGY;ONCOLOGY;

I

The mark consists of a stylized antibody design in the shape of a letter Y and containing the letter I, surrounded by a circle in the shape of a double helix; and the color orange appears in the I, the colors black and white represent outlining and are not part of the mark. ;NON MEDICATED PREPARATIONS FOR CARE OF THE SKIN AND SCALP; SKIN MOISTURIZER; SUNSCREEN; LIP BALM;The color(s) orange is/are claimed as a feature of the mark.;